Jazz Pharmaceuticals To Showcase At BofA Securities Global Health Care Conference 2024

DUBLIN -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a leading global biopharmaceutical company, has announced its participation in the upcoming BofA Securities 2024 Global Health Care Conference. This significant event is scheduled for Wednesday, in Las Vegas, marking a pivotal moment for the company to engage with the healthcare investment community. The conference will feature a fireside chat with Jazz Pharmaceuticals' management at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST, providing insights into the company's latest developments and strategic direction.

Interested parties can access a live audio webcast of the discussion through the Investors section of Jazz Pharmaceuticals' website at https://investor.jazzpharma.com/investors/events-presentations. For those unable to join live, a replay will be available on the website for 30 days post-event, ensuring that stakeholders have the opportunity to engage with the content at their convenience.

Jazz Pharmaceuticals plc stands at the forefront of the biopharmaceutical industry, committed to innovating treatments that significantly improve the lives of patients and their families. The company's mission is centered around developing groundbreaking medicines for individuals facing serious diseases, particularly when therapeutic options are scarce or non-existent. Jazz Pharmaceuticals boasts a diverse portfolio of marketed medicines, with a focus on sleep disorders and epilepsy, alongside an expanding suite of cancer treatments.

The company's dedication to patient-centric and science-driven initiatives underpins its ongoing research and development efforts. These efforts are aimed at advancing a robust pipeline of novel therapeutics in key areas such as oncology and neuroscience. With its global headquarters in Dublin, Ireland, Jazz Pharmaceuticals maintains a strong international presence through its research and development laboratories, manufacturing facilities, and dedicated workforce spread across various countries.

For more information about Jazz Pharmaceuticals and its commitment to transforming patient lives through innovation, please visit www.jazzpharmaceuticals.com.

For investor inquiries, please contact Andrea N. Flynn, Ph.D., Vice President and Head of Investor Relations at Jazz Pharmaceuticals plc via [email protected] or by phone in Ireland at +353 1 634 3211 or in the U.S. at +1 650 496 2717.

Media representatives seeking further information should reach out to Kristin Bhavnani, Head of Global Corporate Communications at Jazz Pharmaceuticals plc, through [email protected] or by phone in Ireland at +353 1 637 2141 or in the U.S. at +1 215 867 4948.

This announcement underscores Jazz Pharmaceuticals' ongoing commitment to leadership in the global healthcare landscape, highlighting its strategic engagements and continuous efforts to advance medical science for better patient outcomes.